E. Lévy

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients.

Karen Leroy, V Dumas, Nadine Martin‐Garcia et al. · PubMed · 2001 · 106 citations

Medicine, Oncology, Pathology +15

Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients

Anne Fajac, Joseph Gligorov, Keyvan Rezaï et al. · British Journal of Cancer · 2010 · 38 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC)

Winald R. Gerritsen, Alfons J. van den Eertwegh, Tanja D. de Gruijl et al. · Journal of Clinical Oncology · 2006 · 34 citations

Medicine, Immunology, Oncology +17

Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group

Isabelle Ray‐Coquard, B. Weber, J Crétin et al. · British Journal of Cancer · 2009 · 24 citations · Full text

Medicine, Oncology, Pharmacology +17